Sotorasib is a first-in-class, selective, irreversible targeted agent with regulatory approval by the FDA for KRAS G12C-mutated locally advanced or metastatic NSCLC patients, who have received at least one prior systemic therapy. This evidence concerns the gene KRAS and non-small cell lung carcinoma.